<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FAMCICLOVIR  - famciclovir tablet, film coated </strong><br>Macleods Pharmaceuticals Limited<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use  <br>FAMCICLOVIR Tablets safely and effectively. See full prescribing information for FAMCICLOVIR  Tablets.<br>FAMCICLOVIR Tablets for oral use<br>Initial U.S. Approval: 1994<br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<br><p class="Highlighta">Famciclovir, USP a prodrug of penciclovir, is a nucleoside analogue DNA polymerase inhibitor indicated for: <br><span class="Underline">Immunocompetent Adult Patients</span>(<a href="#Section_1.1">1.1</a>)<br>• <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes labialis</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>) <br>     o Treatment of recurrent episodes <br>• <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span> <br>     o Treatment of recurrent episodes <br>     o Suppressive therapy of recurrent episodes <br>• <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>) <br><span class="Underline">HIV-Infected Adult Patients</span>(<a href="#Section_1.2">1.2</a>) </p>
<span class="Underline"><br></span><p class="Highlighta">• Treatment of recurrent episodes of orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span><br><span class="Underline">Limitation of Use</span>(<a href="#Section_1.3">1.3</a>)<br>The efficacy and safety of famciclovir have not been established for:<br>• Patients &lt;18 years of age <br>• Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in HIV-  infected patients<br>• Black and African American patients with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table border="0" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="2" valign="top">
<br><span class="Bold">Immunocompetent Adult Patients (<a href="#Section_2.1">2.1</a>)</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes labialis</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>)</td>
<td class="Rrule" valign="top"> 1500 mg as a single dose</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"> <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">        Treatment of recurrent episodes</td>
<td class="Rrule" valign="top"> 1000 mg twice daily for 1 day</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">        Suppressive therapy</td>
<td class="Rrule" valign="top"> 250 mg twice daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>)</td>
<td class="Rrule" valign="top"> 500 mg every 8 hours for 7 days</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="2" valign="top">
<br> <span class="Bold">HIV-Infected Adult Patients (<a href="#Section_2.1">2.1</a>)</span>
</td></tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"> Recurrent episodes of orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span></td>
<td class="Rrule" valign="top"> 500 mg twice daily for 7 days</td>
</tr>
</tbody></table>
<br><p class="Highlighta">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Adjust dose based on creatinine clearance. (<a href="#Section_2.3">2.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<br><p class="Highlighta">Tablets : 125mg, 250mg, 500mg (<a href="#Section_3">3</a>)  </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product, its components, or  Denavir<span class="Sup">® </span>(penciclovir cream) (<a href="#Section_4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<br><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>: May occur in patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who receive higher than recommended doses of famciclovir for their level of renal function. Reduce dosage in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#Section_2.3">2.3,</a><a href="#Section_8.6">8.6</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<br><p class="Highlighta">The most common adverse events reported in at least 1 indication by &gt;10% of adult patients are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. (<a href="#Section_6.1">6.1</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA Inc. at 1-888-943-3210 or FDA at 1-800-FDA-1088 or </span><span class="Bold">www.fda.gov/medwatch</span> </p>
<span class="Bold"><br></span>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<br><p class="Highlighta">Probenecid: May increase penciclovir levels. Monitor for evidence of penciclovir toxicity (<a href="#Section_7.2">7.2</a>)  </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<br><p class="Highlighta">Nursing mothers:  Famciclovir tablets should not be used in nursing mothers unless the potential benefits outweigh the potential risks associated with treatment.(<a href="#Section_8.3">8.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS &amp; USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Immunocompetent Adult Patient</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 HIV-Infected Adult Patients</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitation of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE &amp; ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Recommendation in Immunocompetent Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosing Recommendation in HIV-Infected Adult Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosing Recommendation in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS &amp; STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience in Adult Patient</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potential for famciclovir to Affect Other Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Potential for Other Drugs to Affect Penciclovir</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Black and African American Patients</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Virology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis &amp; Mutagenesis &amp; Impairment Of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span>)</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Recurrent Orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> in HIV-Infected Patients</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span>)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span>)</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span></a></h2>
<h2><a href="#section-15.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span>)</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS &amp; USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Immunocompetent Adult Patient</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes labialis</span>(<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>):</span> Famciclovir, USP is indicated for the treatment of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>. <br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span>: <br></span><span class="Italics">Recurrent episodes:</span> Famciclovir, USP is indicated for the treatment of recurrent episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. The efficacy of famciclovir, USP when initiated more than 6 hours after onset of symptoms or lesions has not been established. <br><br><span class="Italics">Suppressive therapy:</span> Famciclovir, USP is indicated for chronic suppressive therapy of recurrent episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. The efficacy and safety of famciclovir, USP for the suppression of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> beyond 1 year have not been established. <br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>):</span> Famciclovir, USP is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>. The efficacy of famciclovir, USP when initiated more than 72 hours after onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 HIV-Infected Adult Patients</h2>
<p class="First"><span class="Underline">Recurrent orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>:</span> Famciclovir, USP is indicated for the treatment of recurrent episodes of orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in HIV-infected adults. The efficacy of famciclovir, USP when initiated more than 48 hours after onset of symptoms or lesions has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitation of Use</h2>
<p class="First">The efficacy and safety of famciclovir, USP have not been established for:</p>
<ul class="Disc">
<li>Patients &lt;18 years of age </li>
<li>Patients with first episode of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> </li>
<li>Patients with ophthalmic zoster </li>
<li>Immunocompromised patients other than for the treatment of recurrent orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in HIV-infected patients </li>
<li>Black and African American patients with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE &amp; ADMINISTRATION</h1>
<br><p class="First">Famciclovir Tablets may be taken with or without food.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Recommendation in Immunocompetent Adult Patients</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes labialis</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>):</span> The recommended dosage of famciclovir for the treatment of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> is 1500 mg as a single dose. Therapy should be initiated at the first sign or symptom of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or lesion). <br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span>: <br><br></span><span class="Italics">Recurrent episodes</span>: The recommended dosage of famciclovir for the treatment of recurrent episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 1000 mg twice daily for 1 day. Therapy should be initiated at the first sign or symptom of a recurrent episode (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or lesion). <br><br><span class="Italics">Suppressive therapy:</span> The recommended dosage of famciclovir for chronic suppressive therapy of recurrent episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 250 mg twice daily. <br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>):</span> The recommended dosage of famciclovir for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> is 500 mg every 8 hours for 7 days. Therapy should be initiated as soon as <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> is diagnosed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosing Recommendation in HIV-Infected Adult Patients</h2>
<p class="First"><span class="Underline">Recurrent orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>:</span> The recommended dosage of famciclovir for the treatment of recurrent orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in HIV-infected patients is 500 mg twice daily for 7 days. Therapy should be initiated at the first sign or symptom of a recurrent episode (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or lesion).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosing Recommendation in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage recommendations for adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are provided in Table 1 <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.6">8.6</a>), Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].<br><br></span><span class="Bold">Table 1 Dosage Recommendation for Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br></span></p>
<table border="0" cellpadding="0" cellspacing="0" width="732"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Indication and Normal Dosage <br>            Regimen</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Creatinine <br>            Clearance <br>            (mL/min.)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Adjusted Dosage <br>            Regimen Dose (mg)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Dosing Interval</span><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="4" valign="top">
<span class="Underline">Single-Day Dosing Regimens</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="5" valign="top">Recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span><br>1000 mg every 12 hours for 1 day<br>
</td>
<td class="Rrule" align="center" valign="top">≥60<br>
</td>
<td class="Rrule" align="center" valign="top">1000<br>
</td>
<td class="Rrule" align="center" valign="top">every 12 hours for 1 day<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">40 to 59<br>
</td>
<td class="Rrule" align="center" valign="top">500<br>
</td>
<td class="Rrule" align="center" valign="top">every 12 hours for 1 day<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">20 to 39<br>
</td>
<td class="Rrule" align="center" valign="top">500<br>
</td>
<td class="Rrule" align="center" valign="top">single dose<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&lt;20<br>
</td>
<td class="Rrule" align="center" valign="top">250<br>
</td>
<td class="Rrule" align="center" valign="top">single dose<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">HD*<br>
</td>
<td class="Rrule" align="center" valign="top">250<br>
</td>
<td class="Rrule" align="center" valign="top">single dose following <br>            dialysis<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="5" valign="top">Recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span><br>            1500 mg single dose<br>
</td>
<td class="Rrule" align="center" valign="top">≥60<br>
</td>
<td class="Rrule" align="center" valign="top">1500<br>
</td>
<td class="Rrule" align="center" valign="top">single dose<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">40 to 59<br>
</td>
<td class="Rrule" align="center" valign="top">750<br>
</td>
<td class="Rrule" align="center" valign="top">single dose<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">20 to 39<br>
</td>
<td class="Rrule" align="center" valign="top">500<br>
</td>
<td class="Rrule" align="center" valign="top">single dose<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&lt;20<br>
</td>
<td class="Rrule" align="center" valign="top">250<br>
</td>
<td class="Rrule" align="center" valign="top">single dose<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">HD*<br>
</td>
<td class="Rrule" align="center" valign="top">250<br>
</td>
<td class="Rrule" align="center" valign="top">single dose following <br>            dialysis<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="4" valign="top">
<span class="Underline">Multiple-Day Dosing Regimens</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="5" valign="top"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> <br>500 mg every 8 hours<br>
</td>
<td class="Rrule" align="center" valign="top">≥60<br>
</td>
<td class="Rrule" align="center" valign="top">500<br>
</td>
<td class="Rrule" align="center" valign="top">every 8 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">40 to 59<br>
</td>
<td class="Rrule" align="center" valign="top">500<br>
</td>
<td class="Rrule" align="center" valign="top">every 12 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">20 to 39<br>
</td>
<td class="Rrule" align="center" valign="top">500<br>
</td>
<td class="Rrule" align="center" valign="top">every 24 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&lt;20<br>
</td>
<td class="Rrule" align="center" valign="top">250<br>
</td>
<td class="Rrule" align="center" valign="top">every 24 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">HD*<br>
</td>
<td class="Rrule" align="center" valign="top">250<br>
</td>
<td class="Rrule" align="center" valign="top">following each dialysis<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="4" valign="top">Suppression of Recurrent <br>            <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> <br>            250 mg every 12 hours<br>
</td>
<td class="Rrule" align="center" valign="top">≥40<br>
</td>
<td class="Rrule" align="center" valign="top">250<br>
</td>
<td class="Rrule" align="center" valign="top">every 12 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">20 to 39<br>
</td>
<td class="Rrule" align="center" valign="top">125<br>
</td>
<td class="Rrule" align="center" valign="top">every 12 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&lt;20<br>
</td>
<td class="Rrule" align="center" valign="top">125<br>
</td>
<td class="Rrule" align="center" valign="top">every 24 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">HD*<br>
</td>
<td class="Rrule" align="center" valign="top">125<br>
</td>
<td class="Rrule" align="center" valign="top">following each dialysis<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="4" valign="top">Recurrent Orolabial <br>            or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> <br>            in HIV-Infected Patients <br>            500 mg every 12 hours<br>
</td>
<td class="Rrule" align="center" valign="top">≥40<br>
</td>
<td class="Rrule" align="center" valign="top">500<br>
</td>
<td class="Rrule" align="center" valign="top">every 12 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">20 to 39<br>
</td>
<td class="Rrule" align="center" valign="top">500<br>
</td>
<td class="Rrule" align="center" valign="top">every 24 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&lt;20<br>
</td>
<td class="Rrule" align="center" valign="top">250<br>
</td>
<td class="Rrule" align="center" valign="top">every 24 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">HD*<br>
</td>
<td class="Rrule" align="center" valign="top">250<br>
</td>
<td class="Rrule" align="center" valign="top">following each dialysis<br>
</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" colspan="4" valign="top">
<span class="Sup">*</span>Hemodialysis<br>
</td></tr>
</tbody></table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First">Famciclovir tablets are available in 3 strengths: <br><br>•25 mg: White to off white, round film-coated, biconvex, engraved with "ML 67" on one side and plain on the other side. <br><br>•250 mg: White to off white, round film-coated, biconvex, engraved with "ML 70" on one side and plain on the other side. <br><br>•500 mg: White to off white, oval film-coated, biconvex, engraved with "ML 72" on one side and plain on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Famciclovir tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product, its components, or Denavir<span class="Sup">®</span> (penciclovir cream).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>:</span> Cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been reported in patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who have received inappropriately high doses of famciclovir for their level of renal function. Dosage reduction is recommended when administering famciclovir tablets to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>), Use in Specific Populations (<a href="#Section_8.6">8.6</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<br><p class="First"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> is discussed in greater detail in other sections of the label <span class="Italics">[see Warnings and Precautions (<a href="#Section_5">5</a>)]. <br><br></span>The most common adverse events reported in at least 1 indication by &gt;10% of adult patients treated with famciclovir are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience in Adult Patient</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. <br><br><span class="Underline">Immunocompetent patients:</span> The safety of famciclovir has been evaluated in active- and placebo-controlled clinical studies involving 816 famciclovir treated patients with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> (famciclovir , 250 mg three times daily to 750 mg three times daily); 163 famciclovir treated patients with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> ( famciclovir, 1000 mg twice daily); 1,197 patients with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> treated with famciclovir as suppressive therapy (125 mg once daily to 250 mg three times daily) of which 570 patients received famciclovir (open-labeled and/or double-blind) for at least 10 months; and 447 famciclovir treated patients with <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> ( famciclovir, 1500 mg once daily or 750 mg twice daily). Table 2 lists selected adverse events.</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span></span></caption>
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Patients may have entered into more than one clinical trial</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>7 days of treatment</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>1 day of treatment</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>daily treatment</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="9" valign="top">
<br><span class="Bold">Table 2 Selected Adverse Events (all grades and without regard to causality) Reported by ≥2% of Patients in Placebo-controlled famciclovir Trials<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="9" valign="top">
<br> <span class="Bold">Incidence</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="2" valign="top">
<br><br><br><span class="Bold">Event</span><br><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<br><span class="Bold"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></span>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<br><span class="Bold">Recurrent <br>            <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></span>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<br><span class="Bold"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>- <br>            Suppression<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a></span>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<br><span class="Bold"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span><a href="#footnote-3" class="Sup">‡</a><br></span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<br><span class="Bold">Famciclovir</span><br><span class="Bold">(n=273)<br>            %</span>
</td>
<td class="Rrule" valign="top">
<br><br><span class="Bold">Placebo <br>            (n=146)<br>             %</span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Famciclovir</span><br><span class="Bold">(n=163)<br>            %</span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Placebo</span><br><span class="Bold">(n=166)<br>            %</span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Famciclovir</span><br><span class="Bold">(n=458)<br>            %</span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Placebo<br>            (n=63)<br>            %</span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Famciclovir</span><br><span class="Bold">(n=447)<br>            %</span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Placebo<br>            (n=254)</span><br><span class="Bold"> %</span>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="9" valign="top"><span class="Bold"> Nervous System</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center" valign="top">
<br>22.7</td>
<td class="Rrule" align="center" valign="top">
<br>17.8</td>
<td class="Rrule" align="center" valign="top">
<br>13.5</td>
<td class="Rrule" align="center" valign="top">
<br>5.4</td>
<td class="Rrule" align="center" valign="top">
<br>39.3</td>
<td class="Rrule" align="center" valign="top">
<br>42.9</td>
<td class="Rrule" align="center" valign="top">
<br>8.5</td>
<td class="Rrule" align="center" valign="top">
<br>6.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center" valign="top">
<br>2.6</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.9</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></td>
<td class="Rrule" align="center" valign="top">
<br>0.7</td>
<td class="Rrule" align="center" valign="top">
<br>0.7</td>
<td class="Rrule" align="center" valign="top">
<br>0.6</td>
<td class="Rrule" align="center" valign="top">
<br>0.6</td>
<td class="Rrule" align="center" valign="top">
<br>3.1</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.2</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="9" valign="top">
<br><span class="Bold">Gastrointestinal</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center" valign="top">
<br>12.5</td>
<td class="Rrule" align="center" valign="top">
<br>11.6</td>
<td class="Rrule" align="center" valign="top">
<br>2.5</td>
<td class="Rrule" align="center" valign="top">
<br>3.6</td>
<td class="Rrule" align="center" valign="top">
<br>7.2</td>
<td class="Rrule" align="center" valign="top">
<br>9.5</td>
<td class="Rrule" align="center" valign="top">
<br>2.2</td>
<td class="Rrule" align="center" valign="top">
<br>3.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center" valign="top">
<br>7.7</td>
<td class="Rrule" align="center" valign="top">
<br>4.8</td>
<td class="Rrule" align="center" valign="top">
<br>4.9</td>
<td class="Rrule" align="center" valign="top">
<br>1.2</td>
<td class="Rrule" align="center" valign="top">
<br>9.0</td>
<td class="Rrule" align="center" valign="top">
<br>9.5</td>
<td class="Rrule" align="center" valign="top">
<br>1.6</td>
<td class="Rrule" align="center" valign="top">
<br>0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center" valign="top">
<br>4.8</td>
<td class="Rrule" align="center" valign="top">
<br>3.4</td>
<td class="Rrule" align="center" valign="top">
<br>1.2</td>
<td class="Rrule" align="center" valign="top">
<br>0.6</td>
<td class="Rrule" align="center" valign="top">
<br>3.1</td>
<td class="Rrule" align="center" valign="top">
<br>1.6</td>
<td class="Rrule" align="center" valign="top">
<br>0.7</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="center" valign="top">
<br>1.5</td>
<td class="Rrule" align="center" valign="top">
<br>0.7</td>
<td class="Rrule" align="center" valign="top">
<br>0.6</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>4.8</td>
<td class="Rrule" align="center" valign="top">
<br>1.6</td>
<td class="Rrule" align="center" valign="top">
<br>0.2</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center" valign="top">
<br>1.1</td>
<td class="Rrule" align="center" valign="top">
<br>3.4</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>1.2</td>
<td class="Rrule" align="center" valign="top">
<br>7.9</td>
<td class="Rrule" align="center" valign="top">
<br>7.9</td>
<td class="Rrule" align="center" valign="top">
<br>0.2</td>
<td class="Rrule" align="center" valign="top">
<br>0.4</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="9" valign="top">
<br><span class="Bold">Body as a Whole</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center" valign="top">
<br>4.4</td>
<td class="Rrule" align="center" valign="top">
<br>3.4</td>
<td class="Rrule" align="center" valign="top">
<br>0.6</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>4.8</td>
<td class="Rrule" align="center" valign="top">
<br>3.2</td>
<td class="Rrule" align="center" valign="top">
<br>1.6</td>
<td class="Rrule" align="center" valign="top">
<br>0.4</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="9" valign="top">
<br><span class="Bold">Skin and Appendages</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center" valign="top">
<br>3.7</td>
<td class="Rrule" align="center" valign="top">
<br>2.7</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.6</td>
<td class="Rrule" align="center" valign="top">
<br>2.2</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center" valign="top">
<br>0.4</td>
<td class="Rrule" align="center" valign="top">
<br>0.7</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>3.3</td>
<td class="Rrule" align="center" valign="top">
<br>1.6</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="9" valign="top">
<br><span class="Bold">Reproductive Female</span>
</td></tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
<td class="Rrule" align="center" valign="top">
<br>0.7</td>
<td class="Rrule" align="center" valign="top">
<br>1.8</td>
<td class="Rrule" align="center" valign="top">
<br>0.6</td>
<td class="Rrule" align="center" valign="top">
<br>7.6</td>
<td class="Rrule" align="center" valign="top">
<br>6.3</td>
<td class="Rrule" align="center" valign="top">
<br>0.4</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
</tr>
</tbody>
</table>
<p>Table 3 selected laboratory abnormalities in <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> suppression trials</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Percentage of patients with laboratory abnormalities that were increased or decreased from baseline and were outside of specified ranges.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>n values represent the minimum number of patients assessed for each laboratory parameter.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="3" valign="top">
<br><span class="Bold"> Table 3 Selected Laboratory Abnormalities in <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Suppression Studies<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="Bold">Parameter</span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Famciclovir <br>            (n = 660)<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a><br>            %</span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Placebo <br>            (n = 210)<a href="#footnote-6" class="Sup">†</a><br>            %</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (&lt;0.8 x NRL)</td>
<td class="Rrule" align="center" valign="top">
<br>0.1</td>
<td class="Rrule" align="center" valign="top">
<br>0.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (&lt;0.75 x NRL)</td>
<td class="Rrule" align="center" valign="top">
<br>1.3</td>
<td class="Rrule" align="center" valign="top">
<br>0.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt;0.8 x NRL)</td>
<td class="Rrule" align="center" valign="top">
<br>3.2</td>
<td class="Rrule" align="center" valign="top">
<br>1.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br>AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) (&gt;2 x NRH)</td>
<td class="Rrule" align="center" valign="top">
<br>2.3</td>
<td class="Rrule" align="center" valign="top">
<br>1.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br>ALT (SGPT) (&gt;2 x NRH)</td>
<td class="Rrule" align="center" valign="top">
<br>3.2</td>
<td class="Rrule" align="center" valign="top">
<br>1.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br>Total Bilirubin (&gt;1.5 x NRH)</td>
<td class="Rrule" align="center" valign="top">
<br>1.9</td>
<td class="Rrule" align="center" valign="top">
<br>1.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br>Serum Creatinine (&gt;1.5 x NRH)</td>
<td class="Rrule" align="center" valign="top">
<br>0.2</td>
<td class="Rrule" align="center" valign="top">
<br>0.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br>Amylase (&gt;1.5 x NRH)</td>
<td class="Rrule" align="center" valign="top">
<br>1.5</td>
<td class="Rrule" align="center" valign="top">
<br>1.9</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<br>Lipase (&gt;1.5 x NRH)</td>
<td class="Rrule" align="center" valign="top">
<br>4.9</td>
<td class="Rrule" align="center" valign="top">
<br>4.7</td>
</tr>
</tbody>
</table>
<p>NRH = Normal Range High. <br>NRL = Normal Range Low.<br><br><span class="Underline">HIV-infected patients:</span> In HIV-infected patients, the most frequently reported adverse events for famciclovir (500 mg twice daily; n=150) and acyclovir (400 mg, 5x/day; n=143), respectively, were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (17% vs. 15%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (11% vs. 13%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (7% vs. 11%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (5% vs. 4%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (4% vs. 2%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3% vs. 6%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The adverse events listed below have been reported during postapproval use of famciclovir tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: <br><br><span class="Italics">Blood and lymphatic system disorders:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> <br><br><span class="Italics">Hepatobiliary disorders:</span> <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> <br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <br><br><span class="Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> (including <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span> occurring predominantly in the elderly), <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> <br><br><span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (e.g., face, eyelid, periorbital, and <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>), <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span> <br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potential for famciclovir to Affect Other Drugs</h2>
<p class="First">The steady-state pharmacokinetics of digoxin were not altered by concomitant administration of multiple doses of famciclovir (500 mg three times daily). No clinically significant effect on the pharmacokinetics of zidovudine, its metabolite zidovudine glucuronide, or emtricitabine was observed following a single oral dose of 500 mg famciclovir coadministered with zidovudine or emtricitabine. <br><br>An<span class="Italics"> in vitro</span> study using human liver microsomes suggests that famciclovir is not an inhibitor of CYP3A4 enzymes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Potential for Other Drugs to Affect Penciclovir</h2>
<p class="First">No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine, when given shortly after an antacid (magnesium and aluminum hydroxide), or concomitantly with emtricitabine. No clinically significant effect on penciclovir pharmacokinetics was observed following multiple-dose (three times daily) administration of famciclovir (500 mg) with multiple doses of digoxin.<br><br>Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir. <br><br>The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase. Interactions with other drugs metabolized by this enzyme and/or inhibiting this enzyme could potentially occur. Clinical interaction studies of famciclovir with cimetidine and promethazine, in vitro inhibitors of aldehyde oxidase, did not show relevant effects on the formation of penciclovir. Raloxifene, a potent aldehyde oxidase inhibitor in vitro, could decrease the formation of penciclovir. However, a clinical drug-drug interaction study to determine the magnitude of interaction between penciclovir and raloxifene has not been conducted.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy category B.</span> After oral administration, famciclovir (prodrug) is converted to penciclovir (active drug). There are no adequate and well-controlled studies of famciclovir or penciclovir use in pregnant women. No adverse effects on embryofetal development were observed in animal reproduction studies using famciclovir and penciclovir at doses higher than the maximum recommended human dose (MRHD) and human exposure. Because animal reproduction studies are not always predictive of human response, famciclovir should be used during pregnancy only if needed. <br><br>In animal reproduction studies, pregnant rats and rabbits received oral famciclovir at doses (up to 1000 mg/kg/day) that provided 2.7 to 10.8 times (rats) and 1.4 to 5.4 times (rabbits) the human systemic exposure based on AUC. No adverse effects were observed on embryo-fetal development. In other studies, pregnant rats and rabbits received intravenous famciclovir at doses (360 mg/kg/day) 1.5 to 6 times (rats) and (120 mg/kg/day) 1.1 to 4.5 times (rabbits) or penciclovir at doses (80 mg/kg/day) 0.3 to 1.3 times (rats) and (60 mg/kg/day) 0.5 to 2.1 times (rabbits) the MRHD based on body surface area comparisons. No adverse effects were observed on embryo-fetal development.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether famciclovir (prodrug) or penciclovir (active drug) are excreted in human milk. Following oral administration of famciclovir to lactating rats, penciclovir was excreted in breast milk at concentrations higher than those seen in the plasma. There are no data on the safety of famciclovir in infants. Famciclovir should not be used in nursing mothers unless the potential benefits are considered to outweigh the potential risks associated with treatment.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The efficacy of famciclovir tablets has not been established in pediatric patients. The pharmacokinetic profile and safety of famciclovir (experimental granules mixed with OraSweet<span class="Sup">®</span> or tablets) were studied in 2 open-label studies. <br><br>Study 1 was a single-dose pharmacokinetic and safety study in infants 1 month to &lt;1 year of age who had an active herpes simplex virus (HSV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or who were at risk for HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Eighteen subjects were enrolled and received a single dose of famciclovir experimental granules mixed with OraSweet based on the patient’s body weight (doses ranged from 25 mg to 175 mg). These doses were selected to provide penciclovir systemic exposures similar to the penciclovir systemic exposures observed in adults after administration of 500 mg famciclovir. The efficacy and safety of famciclovir have not been established as suppressive therapy in infants following neonatal HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. In addition, the efficacy cannot be extrapolated from adults to infants because there is no similar disease in adults. Therefore, famciclovir is not recommended in infants. <br><br>Study 2 was an open-label, single-dose pharmacokinetic, multiple-dose safety study of famciclovir experimental granules mixed with OraSweet in children 1 to &lt;12 years of age with clinically suspected HSV or <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus (VZV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Fifty-one subjects were enrolled in the pharmacokinetic part of the study and received a single body weight adjusted dose of famciclovir (doses ranged from 125 mg to 500 mg). These doses were selected to provide penciclovir systemic exposures similar to the penciclovir systemic exposures observed in adults after administration of 500 mg famciclovir. Based on the pharmacokinetic data observed with these doses in children, a new weight-based dosing algorithm was designed and used in the multiple-dose safety part of the study. Pharmacokinetic data were not obtained with the revised weight-based dosing algorithm. <br><br>A total of 100 patients were enrolled in the multiple-dose safety part of the study; 47 subjects with active or latent HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and 53 subjects with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. Patients with active or latent HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> received famciclovir twice a day for 7 days. The daily dose of famciclovir ranged from 150 mg to 500 mg twice daily depending on the patient’s body weight. Patients with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> received famciclovir three times daily for 7 days. The daily dose of famciclovir ranged from 150 mg to 500 mg three times daily depending on the patient’s body weight. The clinical adverse events and laboratory test abnormalities observed in this study were similar to these seen in adults. The available data are insufficient to support the use of famciclovir for the treatment of children 1 to &lt;12 years of age with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to HSV for the following reasons: <br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</span> The efficacy of famciclovir for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> has not been established in either pediatric or adult patients. Famciclovir is approved for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> in adult patients. However, extrapolation of efficacy data from adults with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> to children with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> would not be appropriate. Although <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> and <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> are caused by the same virus, the diseases are different. <br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span>:</span> Clinical information on <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in children is limited. Therefore, efficacy data from adults cannot be extrapolated to this population. Further, famciclovir has not been studied in children 1 to &lt;12 years of age with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. None of the children in Study 2 had <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. <br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes labialis</span>:</span> There are no pharmacokinetic and safety data in children 1 to &lt;12 years of age to support a famciclovir dose that provides penciclovir systemic exposures comparable to the penciclovir systemic exposures in adults after a single dose administration of 1500 mg. Moreover, no efficacy data have been obtained in children 1 to &lt;12 years of age with recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>. <br><br>Information from a pediatric study in patients aged 12 years to less than 18 years of age with recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> is approved for Novartis Pharmaceutical Corporation's Famvir® Tablets. However, due to Novartis Pharmaceutical Corporation’s marketing exclusivity rights, a description of those studies is not approved for this famciclovir tablet product.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of 816 patients with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> in clinical studies who were treated with famciclovir, 248 (30.4%) were ≥65 years of age and 103 (13%) were ≥75 years of age. No overall differences were observed in the incidence or types of adverse events between younger and older patients. Of 610 patients with recurrent herpes simplex (type 1 or type 2) in clinical studies who were treated with famciclovir, 26 (4.3%) were &gt;65 years of age and 7 (1.1%) were &gt;75 years of age. Clinical studies of famciclovir in patients with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently compared to younger subjects. <br><br>No famciclovir dosage adjustment based on age is recommended unless renal function is impaired <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>), Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].</span> In general, appropriate caution should be exercised in the administration and monitoring of famciclovir in elderly patients reflecting the greater frequency of decreased renal function and concomitant use of other drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Apparent plasma clearance, renal clearance, and the plasma-elimination rate constant of penciclovir decreased linearly with reductions in renal function. After the administration of a single 500 mg famciclovir oral dose (n=27) to healthy volunteers and to volunteers with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR </span>ranged from 6.4 to 138.8 mL/min), the following results were obtained (Table 4): <br><br><span class="Bold">Table 4 Pharmacokinetic Parameters of Penciclovir in Subjects with Different Degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> <br></span></p>
<table border="0" cellpadding="0" cellspacing="0" width="758">
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>CL<span class="Sub">CR</span> is measured creatinine clearance</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>n=4.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>CL/F consists of bioavailability factor and famciclovir to penciclovir conversion factor.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top"> <span class="Bold">Parameter <br>            (mean ± S.D.)</span>
</td>
<td class="Rrule" valign="top"> <span class="Bold">CL<span class="Sub">CR</span></span><a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a><span class="Bold"> ≥60 <br>            (mL/min.) <br>            (n=15)</span>
</td>
<td class="Rrule" valign="top"> <span class="Bold">CL<span class="Sub">CR</span> 40-59 <br>            (mL/min.)<br>             (n=5)</span>
</td>
<td class="Rrule" valign="top"> <span class="Bold">CL<span class="Sub">CR</span> 20-39 <br>            (mL/min.) <br>            (n=4)</span>
</td>
<td class="Rrule" valign="top"> <span class="Bold">CL<span class="Sub">CR</span> &lt;20  <br>            (mL/min.) <br>            (n=3)</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">CL<span class="Sub">CR</span> (mL/min)</td>
<td class="Rrule" align="center" valign="top">
<br> 88.1 ± 20.6</td>
<td class="Rrule" align="center" valign="top">
<br> 49.3 ± 5.9</td>
<td class="Rrule" align="center" valign="top">
<br> 26.5 ± 5.3</td>
<td class="Rrule" align="center" valign="top">
<br> 12.7 ± 5.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">CL<span class="Sub">R</span> (L/hr)</td>
<td class="Rrule" align="center" valign="top">
<br> 30.1 ± 10.6</td>
<td class="Rrule" align="center" valign="top">
<br>13.0 ± 1.3<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="top">
<br> 4.2 ± 0.9</td>
<td class="Rrule" align="center" valign="top">
<br> 1.6 ± 1.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">CL/F<a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a> (L/hr)</td>
<td class="Rrule" align="center" valign="top">
<br> 66.9 ± 27.5</td>
<td class="Rrule" align="center" valign="top">
<br> 27.3 ± 2.8</td>
<td class="Rrule" align="center" valign="top">
<br> 12.8 ± 1.3</td>
<td class="Rrule" align="center" valign="top">
<br> 5.8 ± 2.8</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"> Half-life (hr)</td>
<td class="Rrule" align="center" valign="top">
<br> 2.3 ± 0.5</td>
<td class="Rrule" align="center" valign="top">
<br> 3.4 ± 0.7</td>
<td class="Rrule" align="center" valign="top">
<br> 6.2 ± 1.6</td>
<td class="Rrule" align="center" valign="top">
<br> 13.4 ± 10.2</td>
</tr>
</tbody>
</table>
<br><p>In a multiple-dose study of famciclovir conducted in subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (n=18), the pharmacokinetics of penciclovir were comparable to those after single doses. <br><br>A dosage adjustment is recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> [n=6], chronic ethanol abuse [n=8], or <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span> [n=1]) had no effect on the extent of availability (AUC) of penciclovir following a single dose of 500 mg famciclovir. However, there was a 44% decrease in penciclovir mean maximum plasma concentration (C<span class="Sub">max</span>) and the time to maximum plasma concentration (t<span class="Sub">max</span>) was increased by 0.75 hours in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to normal volunteers. No dosage adjustment is recommended for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The pharmacokinetics of penciclovir has not been evaluated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Conversion of famciclovir to the active metabolite penciclovir may be impaired in these patients resulting in a lower penciclovir plasma concentrations, and thus possibly a decrease of efficacy of famciclovir (see <a href="#Section_12">section 12 Clinical Pharmacology</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.9"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Black and African American Patients</h2>
<p class="First">In a randomized, double-blind, placebo-controlled trial conducted in 304 immunocompetent black and African American adults with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> there was no difference in median time to healing between patients receiving famciclovir or placebo. In general, the adverse reaction profile was similar to that observed in other famciclovir clinical trials for adult patients [see Adverse Reactions (6.1)]. The relevance of these study results to other indications in black and African American patients is unknown [see <span class="Italics">Clinical Studies (14.2)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<br><p class="First">Appropriate symptomatic and supportive therapy should be given. Penciclovir is removed by hemodialysis</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<br><p class="First">The active ingredient in famciclovir tablets is famciclovir, USP an orally administered prodrug of the antiviral agent penciclovir. Chemically, famciclovir is known as 2-[2-(2-amino-9<span class="Italics">H</span>-purin-9-yl)ethyl]-1,3-propanediol diacetate. Its molecular formula is C<span class="Sub">14</span>H<span class="Sub">19</span>N<span class="Sub">5</span>O<span class="Sub">4</span>; its molecular weight is 321.3. It is a synthetic acyclic guanine derivative and has the following structure:</p>
<br><br><div class="Figure"><img alt="structurer.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=eeeee9c4-8566-4100-8ca4-3df936a3365d&amp;name=structurer.jpg.jpg"></div>
<br><br><p>Famciclovir, USP is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solid. It is freely soluble in acetone and methanol, and sparingly soluble in ethanol and isopropanol. At 25°C famciclovir, USP is freely soluble (&gt;25% w/v) in water initially, but rapidly precipitates as the sparingly soluble (2% to 3% w/v) monohydrate. Famciclovir, USP is not hygroscopic below 85% relative humidity. Partition coefficients are: octanol/water (pH 4.8) P=1.09 and octanol/phosphate buffer (pH 7.4) P=2.08. <br><br>Famciclovir tablets contain 125 mg, 250 mg, or 500 mg of famciclovir, USP together with the following inactive ingredients: hydroxypropyl cellulose, hypromellose, anhydrous lactose, magnesium stearate, polyethylene glycols, sodium starch glycolate and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Famciclovir is an orally administered prodrug of the antiviral agent penciclovir [<span class="Italics">see Clinical Pharmacology (<a href="#Section_12.4">12.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<br><p class="First">Famciclovir is the diacetyl 6-deoxy analog of the active antiviral compound penciclovir. Following oral administration famciclovir undergoes rapid and extensive metabolism to penciclovir and little or no famciclovir is detected in plasma or urine. Penciclovir is predominantly eliminated unchanged by the kidney. Therefore, the dose of famciclovir needs to be adjusted in patients with different degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>)].</span><br><br><span class="Underline">Pharmacokinetics in adults: <br><br></span><span class="Italics">Absorption and Bioavailability:</span> The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects. <br><br>Penciclovir concentrations increased in proportion to dose over a famciclovir dose range of 125 mg to 1000 mg administered as a single dose. Table 5 shows the mean pharmacokinetic parameters of penciclovir after single administration of famciclovir to healthy male volunteers.</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 5 Mean Pharmacokinetic Parameters of Penciclovir in Healthy Adult Subjects<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a></span></caption>
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Based on pharmacokinetic data from 17 studies</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd>AUC (0-inf) (mcg hr/mL)=area under the plasma concentration-time profile extrapolated to infinity.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">‡</a></dt>
<dd>Cmax (mcg/mL)=maximum observed plasma concentration.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">§</a></dt>
<dd>Tmax (h)= time to Cmax.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Dose</td>
<td class="Rrule" valign="top">AUC <span class="Sub">(0-inf)</span> (mcg hr/mL)<a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" valign="top">C<span class="Sub">max  </span>(mcg/mL)<a name="footnote-reference-12" href="#footnote-12" class="Sup">‡</a>
</td>
<td class="Rrule" valign="top">T<span class="Sub">max</span> (h)<a name="footnote-reference-13" href="#footnote-13" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">125 mg</td>
<td class="Rrule" valign="top">2.24</td>
<td class="Rrule" valign="top">0.8 </td>
<td class="Rrule" valign="top">0.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">250 mg</td>
<td class="Rrule" valign="top">4.48</td>
<td class="Rrule" valign="top">1.6</td>
<td class="Rrule" valign="top">0.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">500 mg</td>
<td class="Rrule" valign="top">8.95</td>
<td class="Rrule" valign="top">3.3</td>
<td class="Rrule" valign="top">0.9</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">1000 mg</td>
<td class="Rrule" valign="top">17.9</td>
<td class="Rrule" valign="top">6.6</td>
<td class="Rrule" valign="top">0.9</td>
</tr>
</tbody>
</table>
<br><p>Following oral single-dose administration of 500 mg famciclovir to 7 patients with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, the AUC (mean ± SD), C<span class="Sub">max</span>, and t<span class="Sub">max </span>were 12.1±1.7 mcg hr/mL, 4.0±0.7 mcg/mL, and 0.7±0.2 hours, respectively. The AUC of penciclovir was approximately 35% greater in patients with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> as compared to healthy volunteers. Some of this difference may be due to differences in renal function between the 2 groups. <br><br>There is no accumulation of penciclovir after the administration of 500 mg famciclovir three times daily for 7 days. <br><br>Penciclovir C<span class="Sub">max </span>decreased approximately 50% and t<span class="Sub">max </span>was delayed by 1.5 hours when a capsule formulation of famciclovir was administered with food (nutritional content was approximately 910 Kcal and 26% fat). There was no effect on the extent of availability (AUC) of penciclovir. There was an 18% decrease in C<span class="Sub">max </span>and a delay in t<span class="Sub">max </span>of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal. Because there was no effect on the extent of systemic availability of penciclovir, famciclovir can be taken without regard to meals. <br><br><span class="Italics">Distribution:</span> The volume of distribution (Vdβ) was 1.08±0.17 L/kg in 12 healthy male subjects following a single intravenous dose of penciclovir at 400 mg administered as a 1-hour intravenous infusion. Penciclovir is &lt;20% bound to plasma proteins over the concentration range of 0.1 to 20 mcg/mL. The blood/plasma ratio of penciclovir is approximately 1. <br><br><span class="Italics">Metabolism:</span> Following oral administration, famciclovir is deacetylated and oxidized to form penciclovir. Metabolites that are inactive include 6-deoxy penciclovir, monoacetylated penciclovir, and 6-deoxy monoacetylated penciclovir (5%, &lt;0.5% and &lt;0.5% of the dose in the urine, respectively). Little or no famciclovir is detected in plasma or urine. An in vitro study using human liver microsomes demonstrated that cytochrome P450 does not play an important role in famciclovir metabolism. The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase. Cimetidine and promethazine, <span class="Italics">in vitro</span> inhibitors of aldehyde oxidase, did not show relevant effects on the formation of penciclovir <span class="Italics">in vivo [see Drug Interactions (</span><a href="#Section_7.2">7.2</a><span class="Italics">)]. <br></span><br><span class="Italics">Elimination:</span> Approximately 94% of administered radioactivity was recovered in urine over 24 hours (83% of the dose was excreted in the first 6 hours) after the administration of 5 mg/kg radiolabeled penciclovir as a 1-hour infusion to 3 healthy male volunteers. Penciclovir accounted for 91% of the radioactivity excreted in the urine. <br><br>Following the oral administration of a single 500 mg dose of radiolabeled famciclovir to 3 healthy male volunteers, 73% and 27% of administered radioactivity were recovered in urine and feces over 72 hours, respectively. Penciclovir accounted for 82% and 6-deoxy penciclovir accounted for 7% of the radioactivity excreted in the urine. Approximately 60% of the administered radiolabeled dose was collected in urine in the first 6 hours. <br><br>After intravenous administration of penciclovir in 48 healthy male volunteers, mean ± SD total plasma clearance of penciclovir was 36.6±6.3 L/hr (0.48±0.09 L/hr/kg). Penciclovir renal clearance accounted for 74.5±8.8% of total plasma clearance. <br><br>Renal clearance of penciclovir following the oral administration of a single 500 mg dose of famciclovir to 109 healthy male volunteers was 27.7±7.6 L/hr. Active tubular secretion contributes to the renal elimination of penciclovir. <br><br>The plasma elimination half-life of penciclovir was 2.0±0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3±0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers. The half-life in 17 patients with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> was 2.8±1.0 hours and 2.7±1.0 hours after single and repeated doses, respectively. <br><br><span class="Underline">Special populations: <br><br></span><span class="Italics">Geriatric patients:</span> Based on cross study comparison, penciclovir AUC was 40% higher and penciclovir renal clearance was 22% lower in elderly subjects (n=18, age 65 to 79 years) as compared with younger subjects Some of this difference may be due to differences in renal function between the 2 groups. No famciclovir dosage adjustment based on age is recommended unless renal function is impaired <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>), Use in Specific Populations (<a href="#Section_8.5">8.5</a>).] <br><br></span>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: In subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, apparent plasma clearance, renal clearance, and the plasma-elimination rate constant of penciclovir decreased linearly with reductions in renal function, after both single and repeated dosing <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.6">8.6</a>)].</span> A dosage adjustment is recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span><span class="Italics"> [see Dosage and Administration (<a href="#Section_2.3">2.3</a>)]. <br><br>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>:</span> Mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had no effect on the extent of availability (AUC) of penciclovir <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.7">8.7</a>)].</span> No dosage adjustment is recommended for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of penciclovir has not been evaluated. <br><br><span class="Italics">HIV-infected patients:</span> Following oral administration of a single dose of 500 mg famciclovir to HIV-positive patients, the pharmacokinetic parameters of penciclovir were comparable to those observed in healthy subjects. <br><br><span class="Italics">Gender:</span> The pharmacokinetics of penciclovir were evaluated in 18 healthy male and 18 healthy female volunteers after single-dose oral administration of 500 mg famciclovir. AUC of penciclovir was 9.3±1.9 mcg hr/mL and 11.1±2.1 mcg hr/mL in males and females, respectively. Penciclovir renal clearance was 28.5±8.9 L/hr and 21.8±4.3 L/hr, respectively. <br><br>These differences were attributed to differences in renal function between the 2 groups. No famciclovir dosage adjustment based on gender is recommended. <br><br>Race: A retrospective evaluation was performed to compare the pharmacokinetic parameters obtained in black and Caucasian subjects after single and repeat once-daily, twice-daily, or three times-daily administration of famciclovir 500 mg. Data from a study in healthy volunteers (single dose), a study in subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (single and repeat dose) and a study in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (single dose) did not indicate any significant differences in the pharmacokinetics of penciclovir between black and Caucasian subjects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Virology</h2>
<p class="First"><span class="Underline">Mechanism of action:</span> Famciclovir is a prodrug of penciclovir, which has demonstrated inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus (VZV). In cells infected with HSV-1, HSV-2 or VZV, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted by cellular kinases to the active form penciclovir triphosphate. Biochemical studies demonstrate that penciclovir triphosphate inhibits HSV-2 DNA polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited. Penciclovir triphosphate has an intracellular half-life of 10 hours in HSV-1-, 20 hours in HSV-2-and 7 hours in VZV-infected cells grown in culture. However, the clinical significance of the intracellular half-life is unknown. <br><span class="Underline"><br>Antiviral activity:</span> In cell culture studies, penciclovir is inhibitory to the following herpes viruses: HSV-1, HSV-2 and VZV. The antiviral activity of penciclovir against wild type <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> grown on human foreskin fibroblasts was assessed with a plaque reduction assay and staining with crystal violet 3 days postinfection for HSV and 10 days postinfection for VZV. The median EC<span class="Sub">50</span> values of penciclovir against laboratory and clinical isolates of HSV-1, HSV-2, and VZV were 2 μM (range 1.2 to 2.4 μM, n = 7), 2.6 μM (range 1.6 to 11 μM, n = 6), and 34 μM (range 6.7 to 71 μM, n = 6), respectively.<br><span class="Underline"><br>Resistance:</span> Penciclovir-resistant mutants of HSV and VZV can result from mutations in the viral thymidine kinase (TK) and DNA polymerase genes. Mutations in the viral TK gene may lead to complete loss of TK activity (TK negative), reduced levels of TK activity (TK partial), or alteration in the ability of viral TK to phosphorylate the drug without an equivalent loss in the ability to phosphorylate thymidine (TK altered). The median EC<span class="Sub">50</span> values observed in a plaque reduction assay with penciclovir resistant HSV-1, HSV-2, and VZV were 69 μM(range 14 to 115 μM, n = 6), 46 μM (range 4 to &gt;395 μM, n = 9), and 92 μM (range 51 to 148 μM, n = 4), respectively. The possibility of viral resistance to penciclovir should be considered in patients who fail to respond or experience recurrent viral shedding during therapy. <br><span class="Underline"><br>Cross-resistance</span>: Cross-resistance has been observed among HSV DNA polymerase inhibitors. The most commonly encountered acyclovir resistant mutants that are TK negative are also resistant to penciclovir. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis &amp; Mutagenesis &amp; Impairment Of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis:</span> Two-year dietary carcinogenicity studies with famciclovir were conducted in rats and mice. An increase in the incidence of mammary adenocarcinoma (a common tumor in animals of this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>) was seen in female rats receiving the high dose of 600 mg/kg/day (1.1 to 4.5x the human systemic exposure at the recommended total daily oral dose ranging between 500 mg and 2000 mg, based on area under the plasma concentration curve comparisons [24 hr AUC] for penciclovir). No increases in tumor incidence were reported in male rats treated at doses up to 240 mg/kg/day (0.7 to 2.7x the human AUC), or in male and female mice at doses up to 600 mg/kg/day (0.3 to 1.2x the human AUC). <br><span class="Underline"><br>Mutagenesis:</span> Famciclovir and penciclovir (the active metabolite of famciclovir) were tested for genotoxic potential in a battery of <span class="Italics">in vitro </span>and <span class="Italics">in vivo </span>assays. Famciclovir and penciclovir were negative in <span class="Italics">in vitro </span>tests for gene mutations in bacteria (<span class="Italics">S. typhimurium </span>and <span class="Italics">E. coli</span>) and unscheduled DNA synthesis in mammalian HeLa 83 cells (at doses up to 10,000 and 5,000 mcg/plate, respectively). Famciclovir was also negative in the L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay (5000 mcg/mL), the <span class="Italics">in vivo </span>mouse micronucleus test (4800 mg/kg), and rat dominant lethal study (5000 mg/kg). Famciclovir induced increases in polyploidy in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics">in vitro </span>in the absence of chromosomal damage (1200 mcg/mL). Penciclovir was positive in the L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay for gene mutation/chromosomal aberrations, with and without metabolic activation (1000 mcg/mL). In human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, penciclovir caused chromosomal aberrations in the absence of metabolic activation (250 mcg/mL). Penciclovir caused an increased incidence of micronuclei in mouse bone marrow <span class="Italics">in vivo </span>when administered intravenously at doses highly toxic to bone marrow (500 mg/kg), but not when administered orally.<br><span class="Underline"><br>Impairment of fertility:</span> Testicular toxicity was observed in rats, mice, and dogs following repeated administration of famciclovir or penciclovir. Testicular changes included <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the seminiferous tubules, reduction in sperm count, and/or increased incidence of sperm with abnormal morphology or reduced motility. The degree of toxicity to male reproduction was related to dose and duration of exposure. In male rats, decreased fertility was observed after 10 weeks of dosing at 500 mg/kg/day (1.4 to 5.7x the human AUC). The no observable effect level for sperm and testicular toxicity in rats following chronic administration (26 weeks) was 50 mg/kg/day (0.15 to 0.6x the human systemic exposure based on AUC comparisons). Testicular toxicity was observed following chronic administration to mice (104 weeks) and dogs (26 weeks) at doses of 600 mg/kg/day (0.3 to 1.2x the human AUC) and 150 mg/kg/day (1.3 to 5.1x the human AUC), respectively. <br><br>Famciclovir had no effect on general reproductive performance or fertility in female rats at doses up to 1000 mg/kg/day (2.7 to 10.8x the human AUC). <br><br>Two placebo-controlled studies in a total of 130 otherwise healthy men with a normal sperm profile over an 8-week baseline period and recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> receiving oral famciclovir (250 mg twice daily) (n=66) or placebo (n=64) therapy for 18 weeks showed no evidence of significant effects on sperm count, motility or morphology during treatment or during an 8-week follow-up. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span>)</h2>
<p class="First">A randomized, double-blind, placebo-controlled trial was conducted in 701 immunocompetent adults with recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>. Patients self-initiated therapy within 1 hour of first onset of signs or symptoms of a recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> episode with famciclovir 1500 mg as a single dose (n=227), famciclovir 750 mg twice daily (n=220) or placebo (n=254) for 1 day. The median time to healing among patients with non-aborted lesions (progressing beyond the <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papule</span> stage) was 4.4 days in the famciclovir 1500 mg single-dose group (n=152) as compared to 6.2 days in the placebo group (n=168). The median difference in time to healing between the placebo and famciclovir 1500 mg treated groups was 1.3 days (95% CI: 0.6 – 2.0). No differences in proportion of patients with aborted lesions (not progressing beyond the <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papule</span> stage) were observed between patients receiving famciclovir or placebo: 33% for famciclovir 1500 mg single dose and 34% for placebo. The median time to loss of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> was 1.7 days in famciclovir 1500 mg single dose-treated patients vs. 2.9 days in placebo-treated patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.3"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span></h2>
<br><p class="First"><span class="Underline">Recurrent episodes:</span> A randomized, double-blind, placebo-controlled trial was conducted in 329 immunocompetent adults with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. Patients self-initiated therapy within 6 hours of the first sign or symptom of a recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> episode with either famciclovir 1000 mg twice daily (n=163) or placebo (n=166) for 1 day. The median time to healing among patients with non-aborted lesions (progressing beyond the <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papule</span> stage) was 4.3 days in famciclovir-treated patients (n=125) as compared to 6.1 days in placebo-treated patients (n=145). The median difference in time to healing between the placebo and famciclovir-treated groups was 1.2 days (95% CI: 0.5 to 2.0). Twenty-three percent of famciclovir-treated patients had aborted lesions (no lesion development beyond <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>) vs. 13% in placebo-treated patients. The median time to loss of all symptoms (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>) was 3.3 days in famciclovir-treated patients vs. 5.4 days in placebo-treated patients.<br><br>A randomized (2:1), double-blind, placebo-controlled trial was conducted in 304 immunocompetent black and African American adults with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. Patients self-initiated therapy within 6 hours of the first sign or symptom of a recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> episode with either famciclovir 1000 mg twice daily (n=206) or placebo (n=98) for 1 day. The median time to healing among patients with non-aborted lesions was 5.4 days in famciclovir-treated patients (n=152) as compared to 4.8 days in placebo-treated patients (n=78). The median difference in time to healing between the placebo and famciclovir-treated groups was -0.26 days (95% CI: -0.98 to 0.40). <br><span class="Underline"><br>Suppressive therapy:</span> Two randomized, double-blind, placebo-controlled, 12-month trials were conducted in 934 immunocompetent adults with a history of 6 or more recurrences of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> episodes per year. Comparisons included famciclovir 125 mg three times daily, 250 mg twice daily, 250 mg three times daily, and placebo. At 12 months, 60% to 65% of patients were still receiving famciclovir and 25% were receiving placebo treatment. Recurrence rates at 6 and 12 months in patients treated with the 250 mg twice daily dose are shown in Table 6. <br><br><span class="Bold">Table 6 : Recurrence Rates at 6 and 12 Months in Adults with Recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> on Suppressive Therapy<br></span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="741">
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Based on patient reported data; not necessarily confirmed by a physician.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>Patients recurrence-free at time of last contact prior to withdrawal.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" rowspan="2" valign="top"> </td>
<td class="Rrule" align="center" colspan="2" valign="top">
<br><span class="Bold">Recurrence Rates <br>            at 6 Months</span>
</td>
<td class="Rrule" colspan="2" valign="top">
<br><br><span class="Bold">Recurrence Rates<br>             at 12months</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<br><span class="Bold">Famciclovir 250 mg twice daily<br>             (n=236)</span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Placebo<br>            (n=233</span>)</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">famciclovir 250 mg twice daily <br>            (n=236)  </span>
</td>
<td class="Rrule" align="center" valign="top">
<br><span class="Bold">Placebo <br>            (n=233)</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<br>Recurrence-free </td>
<td class="Rrule" align="center" valign="top">
<br>39% </td>
<td class="Rrule" align="center" valign="top">
<br> 10%</td>
<td class="Rrule" align="center" valign="top">
<br>29% </td>
<td class="Rrule" align="center" valign="top">
<br>6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<br>Recurrences<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a> </td>
<td class="Rrule" align="center" valign="top">
<br> 47%</td>
<td class="Rrule" align="center" valign="top">
<br> 74%</td>
<td class="Rrule" align="center" valign="top">
<br> 53%</td>
<td class="Rrule" align="center" valign="top">
<br> 78%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">
<br>Lost to Follow-up<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="top">
<br> 14%</td>
<td class="Rrule" align="center" valign="top">
<br> 16%</td>
<td class="Rrule" align="center" valign="top">
<br> 17%</td>
<td class="Rrule" align="center" valign="top">
<br> 16%</td>
</tr>
</tbody>
</table>
<p>Famciclovir-treated patients had approximately 1/5 the median number of recurrences as compared to placebo-treated patients. Higher doses of famciclovir were not associated with an increase in efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.4"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Recurrent Orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> in HIV-Infected Patients</h2>
<p class="First">A randomized, double-blind trial compared famciclovir 500 mg twice daily for 7 days (n=150) with oral acyclovir 400 mg 5 times daily for 7 days (n=143) in HIV-infected patients with recurrent orolabial or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> treated within 48 hours of lesion onset. Approximately 40% of patients had a CD<span class="Sub">4</span><span class="Sup">+ </span>count below 200 cells/mm<span class="Sup">3</span>, 54% of patients had anogenital lesions and 35% had orolabial lesions. Famciclovir therapy was comparable to oral acyclovir in reducing new lesion formation and in time to complete healing. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.5"></a><a name="section-13.4"></a><p></p>
<h2>14.4 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span>)</h2>
<br><p class="First">Two randomized, double-blind trials, 1 placebo-controlled and 1 active-controlled, were conducted in 964 immunocompetent adults with uncomplicated <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>. Treatment was initiated within 72 hours of first lesion appearance and was continued for 7 days. </p>
<br><p>In the placebo-controlled trial, 419 patients were treated with either famciclovir 500 mg three times daily (n=138), famciclovir 750 mg three times daily (n=135) or placebo (n=146). The median time to full crusting was 5 days among famciclovir 500 mg-treated patients as compared to 7 days in placebo-treated patients. The times to full crusting, loss of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, loss of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, and loss of crusts were shorter for famciclovir 500 mg-treated patients than for placebo-treated patients in the overall study population. The effects of famciclovir were greater when therapy was initiated within 48 hours of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> onset; it was also more profound in patients 50 years of age or older. Among the 65.2% of patients with at least 1 positive viral culture, famciclovir treated patients had a shorter median duration of viral shedding than placebo-treated patients (1 day and 2 days, respectively).<br><br>There were no overall differences in the duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> before <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> healing between famciclovir-and placebo-treated groups. In addition, there was no difference in the incidence of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> healing (postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>) between the treatment groups. In the 186 patients (44.4% of total study population) who developed postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, the median duration of postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> was shorter in patients treated with famciclovir 500 mg than in those treated with placebo (63 days and 119 days, respectively). No additional efficacy was demonstrated with higher dose of famciclovir. <br><br>In the active-controlled trial, 545 patients were treated with 1 of 3 doses of famciclovir three times daily or with acyclovir 800 mg five times daily. Times to full lesion crusting and times to loss of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> were comparable for all groups and there were no statistically significant differences in the time to loss of postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> between famciclovir and acyclovir-treated groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Famciclovir tablets are supplied as film-coated tablets as follows: 125 mg in bottles of 30; 250 mg in bottles of 30; 500 mg in bottles of 30 <br><br>•  Famciclovir 125 mg tablet: White to off white, round film-coated, biconvex, engraved with "ML 67" on one side and plain on<br>      the other side. <br>     125 mg 30's ......................................NDC 33342-024-07 <br><br>•  Famciclovir 250 mg tablet: White to off white, round film-coated, biconvex, engraved with "ML 70" on one side and plain on <br>      the other side. <br>      250 mg 30's ......................................NDC 33342-025-07 <br><br>•  Famciclovir 500 mg tablet: White to off white, oval film-coated, biconvex, engraved with "ML 72" on one side and plain on the<br>      other side. <br>      500 mg 30's .....................................NDC33342-026-07 <br><br>Store at 20° - 25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. </p>
<br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling (<a href="#Unclassified_Section_21">Patient Information</a>) <br><br>There is no evidence that famciclovir will affect the ability of a patient to drive or to use machines. However, patients who experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or other central nervous system disturbances while taking famciclovir tablets should refrain from driving or operating machinery. <br><br>Because famciclovir tablets contains lactose (Famciclovir 125 mg, 250 mg and 500 mg tablets contain lactose 25.97 mg, 51.95 mg and 103.90 mg, respectively), patients with rare hereditary problems of <span class="product-label-link" type="condition" conceptid="4098477" conceptname="Glucose-galactose malabsorption">galactose intolerance</span>, a severe <span class="product-label-link" type="condition" conceptid="4029736" conceptname="Lactase deficiency">lactase deficiency</span> or glucose-galactose <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> should be advised to discuss with their healthcare provider before taking famciclovir tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span>)</h2>
<p class="First">Patients should be advised to initiate treatment at the earliest sign or symptom of a recurrence of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or lesion). Patients should be instructed that treatment for <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> should not exceed 1 dose. Patients should be informed that famciclovir tablets are not a cure for <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span></h2>
<p class="First">Patients should be informed that famciclovir tablets are not a cure for <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. There are no data evaluating whether famciclovir tablets will prevent transmission of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others. Because <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is a <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span>, patients should avoid contact with lesions or intercourse when lesions and/or symptoms are present to avoid infecting partners. <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span> is frequently transmitted in the absence of symptoms through asymptomatic viral shedding. Therefore, patients should be counseled to use safer sex practices. <br><br>If episodic therapy for recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is indicated, patients should be advised to initiate therapy at the first sign or symptom of an episode. <br><br>There are no data on safety or effectiveness of chronic suppressive therapy of longer than 1-year duration. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span>)</h2>
<p class="First">There are no data on treatment initiated more than 72 hours after onset of zoster <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Patients should be advised to initiate treatment as soon as possible after a diagnosis of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>. <br><br>All brand names listed are the registered trademarks of their respective owners and are not trademarks of the Macleods Pharmaceutical Ltd. <br><br>Manufactured for <br>Macleods Pharma USA,INC, <br>666 Plainsboro Road, Building 200, <br>Suite 230, Plainsboro, NJ 08536 <br><br>Manufactured by: <br>Macleods Pharmaceutical Limited <br>Plot No. 25-27, Survey No. 366, Premier Industrial Estate, <br>Kachigam, Daman-396210, INDIA</p>
<br><p>Revised: February 2014</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_21"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First">Famciclovir Tablets<br><br>Read this Patient Information before you start taking famciclovir tablets and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. <br><br><span class="Bold">What is famciclovir tablet?<br></span>Famciclovir tablet is a prescription antiviral medicine used to:</p>
<ul class="Disc">
<li>treat outbreaks of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">fever blisters</span>) in healthy adults </li>
<li>treat outbreaks of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in healthy adults </li>
<li>decrease the number of outbreaks of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in healthy adults treat outbreaks of herpes simplex lesions in or around the mouth, genitals, and anal area in people infected with HIV </li>
<li>treat <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>) in adults with normal immune system </li>
</ul>
<p>It is not known if famciclovir tablets are safe and effective in children younger than 18 years of age. <br><br>Famciclovir tablets are not a cure for herpes. It is not known if famciclovir tablets can stop the spread of herpes to others. If you are sexually active, you can pass herpes to your partner even if you are taking famciclovir tablets. Herpes can be transmitted even if you do not have active symptoms. You should continue to practice safer sex to lower the chances of spreading <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> to others. Do not have sexual contact with your partner during an outbreak of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> or if you have any symptoms of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. Use a condom made of latex or polyurethane when you have a sexual contact. Ask your healthcare provider for more information about safer sex practices. <br><br><span class="Bold">Who should not take famciclovir tablets? <br></span>Do not take famciclovir tablets if you are allergic to any of its ingredients or to Denavir® (penciclovir cream). See the end of this Patient Information leaflet for a complete list of ingredients in famciclovir tablets. <br><br><span class="Bold">What should I tell my healthcare provider before taking famciclovir tablets? <br></span>Before you start taking famciclovir tablets, tell your healthcare provider if you:</p>
<ul class="Disc">
<li>have kidney or liver problems </li>
<li>have a rare genetic problem with <span class="product-label-link" type="condition" conceptid="4098477" conceptname="Glucose-galactose malabsorption">galactose intolerance</span>, a severe <span class="product-label-link" type="condition" conceptid="4029736" conceptname="Lactase deficiency">lactase deficiency</span> or you do not absorb glucose-galactose (<span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>) </li>
<li>are pregnant or planning to become pregnant. It is not known if famciclovir tablets will harm your unborn baby </li>
<li>are breastfeeding or plan to breastfeed </li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take:</p>
<ul class="Disc">
<li>any other medicines and products you use to treat herpes outbreaks </li>
<li>probenecid (Probalan)</li>
</ul>
<p>Know the medicines you take. Keep a list of them with you to show to your healthcare provider and pharmacist every time you get a new medicine. <br><br><span class="Bold">How should I take famciclovir tablets?</span></p>
<ul class="Disc">
<li>Take famciclovir tablets exactly as prescribed </li>
<li>Your healthcare provider will tell you how many famciclovir tablets to take and when to take them. Your dose of famciclovir tablets and how often you take it may be different depending on your condition </li>
<li>Famciclovir tablets can be taken with or without food </li>
<li>It is important for you to finish all of the medicine as prescribed, even if you begin to feel better </li>
<li>Your symptoms may continue even after you finish all of your famciclovir tablets. This does not mean that you need more medicine, since you have already finished a full course of famciclovir tablets and it will continue to work in your body. Talk to your healthcare provider if you have any questions about your condition and your treatment</li>
</ul>
<p><span class="Bold">What are the possible side effects of famciclovir tablets?</span><br><br>The most common side effects of famciclovir tablets include: </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </li>
</ul>
<p>Talk to your healthcare provider if you have any side effect that bothers you or that does not go away. <br><br>These are not all the possible side effects of famciclovir tablets. Ask your healthcare provider or pharmacist for more information. <br><br>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. <br><br><span class="Bold">How should I store famciclovir tablets? </span></p>
<ul class="Disc"><li>Store famciclovir tablets at room temperature between 59°F and 86°F (15°C to 30°C). </li></ul>
<p><span class="Bold">Keep famciclovir tablets and all medicines out of reach from children.</span><br><br><span class="Bold">General information about famciclovir tablets <br></span>Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use famciclovir tablets for a condition for which it was not prescribed. Do not give famciclovir tablets to other people, even if they have the same symptoms you have. It may harm them. <br><br>This leaflet summarizes the most important information about famciclovir tablets. If you would like more information, talk with your healthcare provider. Your healthcare provider or pharmacist can give you information about famciclovir tablets that is written for health professionals. For more information, call 1-888-943-3210. <br><br><span class="Bold">What are the ingredients in famciclovir tablets? <br><br>Active ingredient:</span> famciclovir <br><br><span class="Bold">Inactive ingredients:</span> hydroxypropyl cellulose, hypromellose, anhydrous lactose, magnesium stearate, polyethylene glycols, sodium starch glycolate and titanium dioxide <br><br>All brand names listed are the registered trademarks of their respective owners and are not trademarks of the Macleods Pharmaceutical Ltd. <br><br>Manufactured for <br>Macleods Pharma USA,INC, <br>666 Plainsboro Road, Building 200, <br>Suite 230, Plainsboro, NJ 08536 <br><br>Manufactured by: <br>Macleods Pharmaceutical Limited <br>Plot No. 25-27, Survey No. 366, Premier Industrial Estate, <br>Kachigam, Daman-396210, INDIA <br><br>Revised: February 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<br><p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL <br></span>Package Label – 125 mg <br>Rx Only    <br>NDC 33342-024-07<br>Famciclovir Tablets<br>125 mg per tablet<br>30 Tablets</p>
<br><div class="Figure"><img alt="125-mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=eeeee9c4-8566-4100-8ca4-3df936a3365d&amp;name=125-mg.jpg"></div>
<br><br><p><span class="Bold">PRINCIPAL DISPLAY PANEL <br></span>Package Label – 250 mg <br>Rx Only    <br>NDC 33342-025-07<br>Famciclovir Tablets<br>250 mg per tablet<br>30 Tablets</p>
<br><br><div class="Figure"><img alt="250-mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=eeeee9c4-8566-4100-8ca4-3df936a3365d&amp;name=250-mg.jpg"></div>
<br><br><p><span class="Bold">PRINCIPAL DISPLAY PANEL <br></span>Package Label – 500 mg <br>Rx Only    <br>NDC 33342-026-07<br>Famciclovir Tablets<br>500 mg per tablet<br>30 Tablets</p>
<br><br><div class="Figure"><img alt="500-mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=eeeee9c4-8566-4100-8ca4-3df936a3365d&amp;name=500-mg.jpg"></div>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FAMCICLOVIR  		
					</strong><br><span class="contentTableReg">famciclovir  tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:33342-024</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FAMCICLOVIR</strong> (PENCICLOVIR) </td>
<td class="formItem">FAMCICLOVIR</td>
<td class="formItem">125 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ML67</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:33342-024-07</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201022</td>
<td class="formItem">12/17/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FAMCICLOVIR  		
					</strong><br><span class="contentTableReg">famciclovir  tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:33342-025</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FAMCICLOVIR</strong> (PENCICLOVIR) </td>
<td class="formItem">FAMCICLOVIR</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ML70</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:33342-025-07</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201022</td>
<td class="formItem">12/17/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FAMCICLOVIR  		
					</strong><br><span class="contentTableReg">famciclovir  tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:33342-026</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FAMCICLOVIR</strong> (PENCICLOVIR) </td>
<td class="formItem">FAMCICLOVIR</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ML72</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:33342-026-07</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201022</td>
<td class="formItem">12/17/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Macleods Pharmaceuticals Limited
							(862128535)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>aef09cf5-9350-438c-9a76-a536eef9f2f5</div>
<div>Set id: eeeee9c4-8566-4100-8ca4-3df936a3365d</div>
<div>Version: 5</div>
<div>Effective Time: 20140201</div>
</div>
</div> <div class="DistributorName">Macleods Pharmaceuticals Limited</div></p>
</body></html>
